INTRODUCTION Leishmaniasis is classified into three clinical presentations: visceral, coetaneous and mucocutaneous. The latter is usually secondary to hematogenous spread after months or years of skin infection and can manifest as infiltrative lesions, ulcerated or vegetating in nose, pharynx, larynx and mouth, associated or not with ganglionics infarction. Laryngeal involvement is part of the ...

Serum IgE levels and the expression of low affinity receptor for IgE (Fc epsilon RII/CD23) are increased in cutaneous leishmaniasis. The ligation of CD23 receptor by IgE-anti-IgE immune complexes results in nitric oxide (NO) production, which is a critical leishmanicidal factor. Human monocytes/macrophages express Fc epsilon RII/CD23 after activation with IFN-gamma and IL-4. In the present stud...

BACKGROUND Leishmaniasis is an endemic disease in Iran. Although many treatments have been suggested for this disease, there hasn't been an effective and safe treatment yet. Regarding the healing effect of honey in the chronic ulcers and its reported therapeutic effect in cutaneous leishmaniasis, we performed a study to better evaluate the efficacy of honey in cutaneous leishmaniasis and its fi...

Visceral leishmaniasis is a systemic infectious disease that can cause to a severe, potentially life-threatening chronic condition in humans. Risk factors for infection in urban areas have been associated with poor living conditions, the presence of sand fly vectors and infected pets. This study aimed to describe sand fly and canine infection in the neighborhoods of human visceral leishmaniasis...

Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis. To evaluate the safety and efficacy of marbofloxacin in dogs with leishmaniasis and dec...

Canine leishmaniasis is a chronic parasitic disease transmitted by small bloodsucking insects. Clinically, affected patients present with progressive wasting, slight or marked reduction in appetite, lymphadenomegaly, splenomegaly, and cutaneous lesions (e.g., dry desquamation [dry seborrhea], ulcers, nodules). A correct diagnosis is based on specific serologic and molecular tests and nonspecifi...

Visceral leishmaniasis is associated with chronic inflammatory stimulation, resulting in different clinical manifestations, ranging from unapparent infection to a systemic disease. In dogs, there are descriptions of neurological involvement with inflammatory infiltrates and specific antibodies in cerebrospinal fluid. To investigate the involvement of the choroid plexus and the blood-CSF barrier...

Background and Objectives: Visceral leishmaniasis is a chronic disease in Africa and Asia, children under 5 years are affecting with L.infantum and older children and young adult with L.donovani Purpose of this study describes the characteristics of epidemiologic and clinicopathophysiologic and response to treatment of patient that affected in East Azarbaijan compared with other endemic areas ...

We report a patient with fever, progressive jaundice and abdominal distension, having marked pallor, icterus, ascites and hepatosplenomegaly. Investigations revealed pancytopenia and deranged liver functions. Doppler study revealed portal hypertension and endoscopy showed grade II oesophageal varices. Liver biopsy suggested leishmanial hepatitis and bone marrow demonstrated multiple LD bodies. ...

Visceral leishmaniasis is a chronic parasitic disease associated with severe immune dysfunction. Treatment options are limited to relatively toxic drugs, and there is no vaccine for humans available. Hence, there is an urgent need to better understand immune responses following infection with Leishmania species by studying animal models of disease and clinical samples from patients. Here, we re...